HUTCHMED (China) Investor Relations Material
Latest events
Investor Update
HUTCHMED (China)
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from HUTCHMED (China) Limited
Access all reports
HUTCHMED Limited is a global biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies and immunotherapies for cancer and immunological diseases. The company integrates innovative science and clinical expertise to develop a robust pipeline of therapies, leveraging its research and development capabilities in China and internationally. HUTCHMED markets its products in various regions and collaborates with global pharmaceutical partners for distribution and development. The company is headquartered in Hong Kong, China, and its shares are listed on the NASDAQ and the London Stock Exchange (LSE).
Key slides for HUTCHMED (China) Limited
H1 2024
HUTCHMED (China) Limited
R&D Update
HUTCHMED (China) Limited
Latest articles
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
)
D. E. Shaw & Co: Inside the Quiet Giant of Quant Finance
A deep dive into D. E. Shaw's evolution from a $28M quant startup to a $65B hedge fund giant, built on research, computing, and quiet consistency.
2 Jul 2025
)
Pershing Square Capital Management: Conviction, Reinvention, and Contrarian Investing
Pershing Square Capital Management has grown into a top-tier hedge fund through reinvention, conviction, and focus on long-term value creation.
2 Jul 2025
Ticker symbol
HCM
Country
🇬🇧 United Kingdom